Kaijin Xu
Impact in
- Microbiology top 0.5%
- Antimicrobial Peptides and Activities
- Infectious Diseases top 0.5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- COVID-19 Clinical Research Studies 18
- Tuberculosis Research and Epidemiology 17
- SARS-CoV-2 and COVID-19 Research 12
- Epidemiology 41
- Hepatitis B Virus Studies 17
- Mycobacterium research and diagnosis 11
- Co-authors
- Lanjuan Li (53 shared papers)Jifang Sheng (33 shared papers)Hongliu Cai (4 shared papers)Yunqing Qiu (7 shared papers)Yi‐Yan Yang (6 shared papers)Huaying Wang (5 shared papers)Xiaowei Xu (3 shared papers)Hainv Gao (3 shared papers)
- Journals
- Infection and Drug Resistance (8 papers)Human Vaccines & Immunotherapeutics (6 papers)BMC Infectious Diseases (4 papers)Frontiers in Medicine (3 papers)Microbiology Spectrum (3 papers)
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Kaijin Xu
112 papers receiving 5.9k citations
Kaijin Xu's Hit Papers
Peers
Comparison fields: 5 of 166
- Microbiology 784
- Infectious Diseases 1.9k
- Obstetrics and Gynecology 327
- Neurology 640
- Hepatology 279
Countries citing papers authored by Kaijin Xu
This map shows the geographic impact of Kaijin Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaijin Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaijin Xu more than expected).
Fields of papers citing papers by Kaijin Xu
This network shows the impact of papers produced by Kaijin Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaijin Xu. The network helps show where Kaijin Xu may publish in the future.
Co-authors
The 25 scholars most cited alongside Kaijin Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 116 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series Hit paper breakdown → | 2020 | 1503 |
| 2 | Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent Hit paper breakdown → | 2009 | 568 |
| 3 | Biodegradable nanostructures with selective lysis of microbial membranes Hit paper breakdown → | 2011 | 534 |
| 4 | 2020 | 338 | |
| 5 | 2020 | 284 | |
| 6 | 2017 | 187 | |
| 7 | 2016 | 134 | |
| 8 | 2020 | 133 | |
| 9 | 2022 | 132 | |
| 10 | 2010 | 111 | |
| 11 | 2013 | 104 | |
| 12 | 2010 | 101 | |
| 13 | 2012 | 91 | |
| 14 | 2021 | 89 | |
| 15 | 2020 | 82 | |
| 16 | 2020 | 75 | |
| 17 | 2006 | 72 | |
| 18 | 2018 | 69 | |
| 19 | 2021 | 65 | |
| 20 | 2020 | 61 |
About Kaijin Xu
Kaijin Xu is a scholar working on Infectious Diseases, Epidemiology, Hepatology, Molecular Biology and Surgery, having authored 116 papers that have together received 6.0k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (18 papers), Hepatitis B Virus Studies (17 papers), Tuberculosis Research and Epidemiology (17 papers), SARS-CoV-2 and COVID-19 Research (12 papers), Mycobacterium research and diagnosis (11 papers), Hepatitis C virus research (10 papers), Hepatitis Viruses Studies and Epidemiology (8 papers) and Antimicrobial Peptides and Activities (7 papers). The work is most often cited by research in Microbiology (784 citations), Infectious Diseases (1.9k citations), Obstetrics and Gynecology (327 citations), Neurology (640 citations) and Hepatology (279 citations). Kaijin Xu has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Lanjuan Li, Jifang Sheng, Hongliu Cai, Yunqing Qiu, Yi‐Yan Yang, Huaying Wang, Xiaowei Xu, Hainv Gao, Weimin Fan and Xiaoxin Wu. Their work appears in journals such as Infection and Drug Resistance, Human Vaccines & Immunotherapeutics, BMC Infectious Diseases, Frontiers in Medicine and Microbiology Spectrum.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.